^
BIOMARKER:
BCR-ABL1 T315I
i
Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1, BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL
Entrez ID:
BCR-ABL1 T315I
CML
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
ALL
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
ALL
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
ALL
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
ALL
nilotinib
Resistant
:
A2
BCR-ABL1 T315I
CML
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
CML
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
CML
nilotinib
Resistant
:
A2
BCR-ABL1 T315I
CML
ABL001
Sensitive
:
B
BCR-ABL1 T315I
CML
HQP1351
Sensitive
:
B
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive
:
C1
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive
:
C3
BCR-ABL1 T315I
CML
imatinib
Resistant
:
C3
BCR-ABL1 T315I
CML
dasatinib + nilotinib
Resistant
:
C3
BCR-ABL1 T315I
CML
PF-114
Sensitive
:
C3
BCR-ABL1 T315I
CML
axitinib
Sensitive
:
C4
BCR-ABL1 T315I
CML
dasatinib + axitinib
Sensitive
:
C4
BCR-ABL1 T315I
CML
NT-157
Sensitive
:
D
BCR-ABL1 T315I
CML
sorafenib
Sensitive
:
D
BCR-ABL1 T315I
CML
CUDC-907
Sensitive
:
D
BCR-ABL1 T315I
CML
ponatinib + GMX1778
Sensitive
:
D
BCR-ABL1 T315I
Leukemia
ponatinib + ABL001
Sensitive
:
D
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
IODVA1
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our